Pioneering Biologics,Empowering Africa
Dedicated to making high-quality biologics accessible through localized innovation
Major Breakthrough
Semaglutide Receives TMDA Marketing Authorization
Africa is entering the Semaglutide era. Our Semaglutide product has officially received marketing authorization from the Tanzania Medicines and Medical Devices Authority (TMDA), marking a significant milestone in bringing world-class metabolic treatments to African patients.
TMDA Approved
Tanzania Medicines and Medical Devices Authority
1.5B+
Population Coverage
WHO PQ
Quality Standard
Green Energy
Self-Sufficient
In Africa, For Africa, To the World
Bridging the Gap. From "Import Dependent" to "Made in Africa"
Four Major Disease Areas
Comprehensive product coverage addressing Africa's critical health needs
Diabetes & Related
Semaglutide, Tirzepatide, Icodec Insulin, IcoSema
Cancer & Related
Bevacizumab, Rituximab, Trastuzumab, Adalimumab, PD-1
HIV Related
Lenacapavir, Long-acting antiretroviral therapies
Vaccines Related
HPV2-HPV9, PCV, Malaria vaccines
